PHILADELPHIA, Jan. 31, 2025 (GLOBE NEWSWIRE) — Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against ASP Isotopes Inc. (“ASP Isotopes” or the “Company”) (NASDAQ: ASPI) on behalf of purchasers of ASP Isotopes securities between October 30, 2024 and November 26, 2024, inclusive (the “Class Period”).
Investors that suffered losses from ASP ISOTOPES (NASDAQ: ASPI) investments can follow the link below for more information regarding the lawsuit:
CLICK HERE to learn more about the lawsuit.
Investors who purchased or acquired ASP ISOTOPES securities during the Class Period may, no later than FEBRUARY 3, 2025, seek to be appointed as a lead plaintiff representative of the class.
Headquartered in Washington, DC, ASP Isotopes is a development-stage advanced materials company focused on the production, enrichment, and sale of isotopes. The Company purports to have multiple isotope enrichment plants currently under development in South Africa.
Investors learned the truth on November 26, 2024, when Fuzzy Panda Research published a report alleging that ASP Isotopes was “using old, disregarded laser enrichment technology to masquerade as a new, cutting-edge Uranium enrichment.” The report, which drew upon interviews with former employees and industry experts, cast doubt on the Company’s “proprietary” technology and characterized the Company’s timeline for building its high-assay low-enriched uranium (HALEU) facilities as misleading to the point of being “delusional.” The report further alleged the Company had significantly overstated the significance of its agreement with TerraPower and misled investors as to the involvement of subsidiary Quantum Leap Energy in the proposed TerraPower relationship.
On this news, the Company’s stock price fell $1.80, or 23.53%, to close at $5.85 per share on November 26, 2024, on unusually heavy trading volume. The stock continued to fall on the subsequent trading date, falling $0.83 or 14.19%, to close at $5.02 per share on November 27, 2024.
For additional information or to learn how to participate in this litigation, please contact Berger Montague: Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Peter Hamner at phamner@bm.net or (215) 875-3048, or CLICK HERE.
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
Contacts:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bm.net
Peter Hamner
Berger Montague PC
phamner@bm.net
- Update on closing timetable for sale of MacGregor - July 1, 2025
- Li Auto Inc. June 2025 Delivery Update - July 1, 2025
- Baltic Horizon Fund publishes its ESG report for 2024 - July 1, 2025
